1-ethyl-3,3,5,5-tetramethylcyclohexylamine | 219810-66-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-ethyl-3,3,5,5-tetramethylcyclohexylamine
• 英文别名: 1-amino-1-ethyl-3,3,5,5-tetramethylcyclohexane；Cyclohexanamine, 1-ethyl-3,3,5,5-tetramethyl-；1-ethyl-3,3,5,5-tetramethylcyclohexan-1-amine
• CAS: 219810-66-9
• 化学式: C₁₂H₂₅N
• 分子量: 183.337
• InChiKey: YKLPCZMZROZLJA-UHFFFAOYSA-N

物化性质

• 沸点：
  210.9±8.0 °C(Predicted)
• 密度：
  0.808±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3,5,5-四甲基环己酮 在 lithium aluminium tetrahydride 、 三(2-氯乙基)胺 、 四氯化钛 作用下， 以 乙醚 、 氯仿 为溶剂， 反应 30.0h， 生成 1-ethyl-3,3,5,5-tetramethylcyclohexylamine
  参考文献：
  名称：

  Synthesis and structure–affinity relationships of 1,3,5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site

  摘要：

  A series of 1,3,5-alkylsubstituted cyclohexylamines 2 were synthesized as ligands for the N-methyl-D-aspartate (NMDA) receptor phencyclidine (PCP) binding site. Pure diastereomers with defined configuration of amino group 2-ax and 2-eq were obtained. The optimal size of 1,3,5-substituents was determined for cyclohexylamines 2 with an equatorial amino group in the lowest energy conformation using Hansch analysis. According to the data, the lipophilic part of cyclohexylamines 2 does not discriminate between hydrophobic regions of the PCP binding site but rather recognizes this site as a whole lipophilic pocket. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00153-7

文献信息

• [EN] METHOD OF PREPARING 3,3,5,5-TETRAMETHYLCYCLOHEXANONE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA 3,3,5,5-TÉTRAMÉTHYLCYCLOHEXANONE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2011000540A1

  公开（公告）日：2011-01-06

  Method of preparing 3,3,5,5-tetramethylcyclohexanone comprising step (i): (i) converting isophorone to 3,3,5,5-tetramethylcyclohexanone in the presence of methylmagnesium chloride. The thus prepared 3,3,5,5-tetramethylcyclohexanone may be employed in a method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof.

  制备3,3,5,5-四甲基环己酮的方法包括步骤(i)：(i) 在存在甲基氯化镁的情况下将异季戊酮转化为3,3,5,5-四甲基环己酮。因此制备的3,3,5,5-四甲基环己酮可用于制备1-氨基-1,3,3,5,5-五甲基环己烷（Neramexane）或其药用可接受的盐的方法中。
• [EN] METHOD OF PREPARING 1-HYDROXY-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 1-HYDROXY-1,3,3,5,5-PENTAMÉTHYLCYCLOHEXANE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2011000536A1

  公开（公告）日：2011-01-06

  Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane comprising step (ii): (ii) converting 3,3,5,5-tetramethylcyclohexanone to 1-hydroxy-1,3,3,5,5- pentamethylcyclohexane by using methylmagnesium chloride. 1-hydroxy-1,3,3,5,5- pentamethylcyclohexane may be used for preparing 1-amino-1,3,3,5,5- pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof.

  制备1-羟基-1,3,3,5,5-五甲基环己烷的方法包括步骤(ii)：(ii) 通过使用氯化甲基镁将3,3,5,5-四甲基环己酮转化为1-羟基-1,3,3,5,5-五甲基环己烷。1-羟基-1,3,3,5,5-五甲基环己烷可用于制备1-氨基-1,3,3,5,5-五甲基环己烷（Neramexane）或其药用可接受的盐。
• [EN] METHOD OF PREPARING NERAMEXANE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE NÉRAMEXANE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2011000538A1

  公开（公告）日：2011-01-06

  Method of producing a salt of 1-amino-1,3,3,5,5-pentamethylcyclohexane comprising steps (i) to (v): (i) converting isophorone to 3,3,5,5-tetramethylcyclohexanone; (ii) converting 3,3,5,5-tetramethylcyclohexanone obtained in step (i) to 1- hydroxy-1,3,3,5,5-pentamethylcyclohexane; (iii) converting 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane obtained in step (ii) to 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane; (iv) converting 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane obtained in step (iii) to 1-amino-1,3,3,5,5-pentamethylcyclohexane; wherein at least one of 3,3,5,5-tetramethylcyclohexanone, 1-hydroxy-1,3,3,5,5- pentamethylcyclohexane, 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane, is not subjected to a purification step.

  生产1-氨基-1,3,3,5,5-五甲基环己烷盐的方法包括步骤(i)至(v)：(i)将异佛尔酮转化为3,3,5,5-四甲基环己酮；(ii)将步骤(i)中得到的3,3,5,5-四甲基环己酮转化为1-羟基-1,3,3,5,5-五甲基环己烷；(iii)将步骤(ii)中得到的1-羟基-1,3,3,5,5-五甲基环己烷转化为1-氯乙酰胺基-1,3,3,5,5-五甲基环己烷；(iv)将步骤(iii)中得到的1-氯乙酰胺基-1,3,3,5,5-五甲基环己烷转化为1-氨基-1,3,3,5,5-五甲基环己烷；其中至少有3,3,5,5-四甲基环己酮、1-羟基-1,3,3,5,5-五甲基环己烷、1-氯乙酰胺基-1,3,3,5,5-五甲基环己烷中的一种未经过纯化步骤。
• METHOD OF PREPARING 3,3,5,5-TETRAMETHYLCYCLOHEXANONE
  申请人：Koller Herbert

  公开号：US20130123541A1

  公开（公告）日：2013-05-16

  Method of preparing 3,3,5,5-tetramethylcyclohexanone comprising step (i): (i) converting isophorone to 3,3,5,5-tetramethylcyclohexanone in the presence of methylmagnesium chloride. The thus prepared 3,3,5,5-tetramethylcyclohexanone may be employed in a method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof.

  制备3,3,5,5-四甲基环己酮的方法包括步骤（i）：（i）在存在甲基氯化镁的情况下将异佛酮转化为3,3,5,5-四甲基环己酮。这样制备的3,3,5,5-四甲基环己酮可用于制备1-氨基-1,3,3,5,5-五甲基环己烷（Neramexane）或其药用可接受的盐的方法中。
• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。